New data from a randomized, double-blind study showed that a combination of Copaxone with the oral antibiotic minocycline reduced T1 Gadolinium enhancing lesions of the brain by 63% and reduced the number of new T2 lesions in patients by 65%. These results trended toward but did not reach statistical significance.
Luanne Metz, professor at the Department of Clinical Neuroscience of the University of Calgary, and principal investigator, said: “The results of this study indicated that further exploration of this combination is warranted, as the established effect of Copaxone on disease activity may be boosted when used in combination with minocycline for the treatment of active relapsing-remitting patients.”